Singularity Hub -
18 Mar 2024 22:45
For the first time, an AI-designed drug is in the second phase of clinical trials. Recently, the team behind the drug published a paper outlining how they developed it so fast. Made by Insilico Medicine, a biotechnology company based in New York and Hong Kong, the drug candidate targets idiopathic pulmonary fibrosis, a deadly disease […]
Share this Article